https://orcid.org/0000-0003-0671-1447

Professor Benjamin Djulbegovic is a Professor at City of Hope where he serves as Director of Program for Evidence-based Analytics at City of Hope. His main academic and research interest lies in attempts to measure and optimize clinical research and practice of medicine by understanding both nature of medical evidence and decision-making. To this effect, his work aims to integrate methods and techniques across evidence-based medicine (EBM), predictive analytics, health outcome research, and decision-sciences with the goal of improvement of health care. The role of uncertainty and rationality in science and clinical medicine has been one of the common themes across his work, particularly evident in his analysis of equipoise and the role of regret. Dr. Djulbegovic has systematically applied science of EBM and decision analysis to the entire fields of hematology and oncology that resulted in two books; the book on “Reasoning and decision-making in hematology” (listed as one of the best books in 1993 according to J Natl Cancer Inst. 1994; 86: 235-236; the book is also translated in Italian as “Il Processo Decisionale in Ematologia,” Centro Scientifico Editore, Torino, 1994). and the book “Decision Making in Oncology (“this is one of the first and best attempts to apply an evidence-based approach to the practice of medical oncology. I cannot imagine owning a better or more useful book, a bargain in its paperback form” – J Natl Cancer Inst. 1998; 90(8): 627). Evidence-based management” was assessed as “one of the first and best attempts to apply an evidence-based approach to the practice of medical oncology”. As of May of 2019, he has published 335 papers in peer-review journals, 195 abstracts and numerous book chapters. He also received numerous awards for his work, which has also been published in major scientific and medical journals including Nature, Lancet, JAMA, New England Journal of Medicine, etc. He has also widely taught on these subjects. During last 20 years, Dr. Djulbegovic has received continuous external funding by both federal and private entities. He was also selected in the Newsweek’s list of Top Cancer Doctors and since 2011 continuously selected in 1% of top US doctors by the US News & World Report in the field of hematology. His h-index is 63; in 2018 he is included in the list of highly cited researchers which “recognizes world-class researchers selected for their exceptional research performance, demonstrated by production of multiple highly cited papers that rank in the top 1% by citations for field and year in Web of Science.”